[[{“value”:”
Apple Tree Partners’ latest startup is Red Queen Therapeutics, developer of stapled peptide drugs that block viral fusion. Its lead program is on track for Phase 2 testing in immunocompromised Covid-19 patients; a preclinical pan-influenza program is in development under a BARDA contract.
The post Startup Red Queen Therapeutics Unveils $55M and Tech to Defeat Elusive Viral Pathogens appeared first on MedCity News.
“}]]
